Early Access

10-KPeriod: FY2025

Corteva, Inc. Annual Report, Year Ended Dec 31, 2025

Filed February 12, 2026For Securities:CTVA

Summary

Corteva, Inc. reported robust performance for the year ended December 31, 2025, with net sales increasing by 3% to $17.4 billion, driven by a 1% rise in price and a 3% increase in volume. This growth was achieved despite a 1% unfavorable currency impact. The company demonstrated strong operational execution, with Cost of Goods Sold (COGS) decreasing to $9.2 billion due to cost-saving initiatives, raw material deflation, and lower commodity prices, partially offset by higher volumes. Income from continuing operations after taxes significantly improved to $1.2 billion from $863 million in the prior year, with Operating EBITDA rising to $3.8 billion from $3.4 billion. Key strategic priorities for Corteva include delivering top-tier technology, increasing market share in seed trait out-licensing, driving operational improvements, and completing the intended separation of its Seed and Crop Protection businesses into two standalone public companies by the second half of 2026. The company also returned approximately $1.5 billion to shareholders through share repurchases and dividends in 2025, underscoring its commitment to shareholder value. Corteva remains focused on innovation and deploying capital with discipline to drive organic and inorganic growth.

Financial Statements
Beta

Key Highlights

  • 1Net sales increased 3% year-over-year to $17.4 billion, driven by a 1% price increase and 3% volume increase.
  • 2Income from continuing operations after taxes significantly improved to $1.2 billion, a substantial increase from $863 million in the prior year.
  • 3Operating EBITDA grew by 14% to $3.8 billion, reflecting operational efficiencies and volume growth.
  • 4The company returned approximately $1.5 billion to shareholders through share repurchases and dividends in 2025.
  • 5Corteva announced its intent to separate its Seed and Crop Protection businesses into two independent publicly traded companies, expected to be completed in the second half of 2026.
  • 6Investment in Research and Development increased to $1.5 billion, supporting the company's innovation pipeline.
  • 7Selling, General, and Administrative (SG&A) expenses as a percentage of net sales increased slightly to 20% from 19%.

Frequently Asked Questions